DAVENPORT & Co LLC Has $6.76 Million Stock Holdings in Zoetis Inc. $ZTS

DAVENPORT & Co LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 43,361 shares of the company’s stock after selling 297 shares during the quarter. DAVENPORT & Co LLC’s holdings in Zoetis were worth $6,763,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. Nova Wealth Management Inc. bought a new position in Zoetis during the 1st quarter worth approximately $25,000. 1248 Management LLC bought a new position in Zoetis during the 1st quarter worth approximately $27,000. Saudi Central Bank bought a new position in Zoetis during the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Finally, ORG Partners LLC raised its holdings in Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock worth $37,000 after purchasing an additional 84 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $142.91 on Wednesday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The company has a market capitalization of $63.33 billion, a price-to-earnings ratio of 24.60, a P/E/G ratio of 2.33 and a beta of 0.90. The firm’s fifty day moving average price is $149.52 and its two-hundred day moving average price is $154.82. Zoetis Inc. has a 1 year low of $139.34 and a 1 year high of $196.55.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of several analyst reports. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research note on Saturday, September 27th. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.